ERS Respiratory Channel

CDN Connection Issue

It appears that your current network does not allow connection to the CDN (Content Delivery Network) required for this service to function properly.

To resolve this issue, please try the following actions :

• Contact your network administrator : Inform them of this restriction so they can adjust the network settings accordingly.

• Use another network : Try connecting from a different network, such as another Wi-Fi network or a mobile connection.

We apologize for the inconvenience and thank you for your understanding.

Abstract

Background: The ROX index (SpO2/FiO2/RR) is a useful predictor of the success of high-flow nasal cannula (HFNC) therapy for acute respiratory failure. However, its applicability as a prognostic factor for patients with acute exacerbation of interstitial pneumonia (AE-IP) remains unclear.

Methods: We retrospectively investigated the ROX index and 30-day mortality in 92 patients with AE-IP who received HFNC from April 2016 to June 2023 at our institution.

Results: Patient characteristics included a median age of 67 years, 73% male, 38% with UIP pattern, and WBC/LDH of 12100/425.The association between 30-day mortality and ROX index at 0 hours (ROX 0) and 12 hours (ROX 12) after HFNC initiation was observed with odds ratios (OR) of 0.80 (95% CI, 0.63-1.00) and 0.66 (95% CI, 0.50-0.85), respectively. Multivariate analysis, including UIP pattern, age, LDH, WBC, pre-exacerbation oxygen therapy, and ROX 12, revealed that only ROX 12 was statistically significant in relation to 30-day mortality (OR 0.67; 95% CI, 0.51-0.88).

Conclusion: The ROX 12 index has the potential to serve as a prognostic factor for AE-IP.

Abstract

#{title}